New antibody drug takes aim at rheumatoid arthritis in first human trial

NCT ID NCT07564154

Recruiting now Disease control Sponsor: Kali Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 12, 2026 · Updated 5 times

Summary

This early-stage trial tests a new drug called KT502 in 27 adults with moderate to severe rheumatoid arthritis. The drug is designed to deplete certain immune cells (B cells) that contribute to joint inflammation. The main goal is to check safety and find the right dose, not yet to see if it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: KT502 (a monoclonal antibody that targets and depletes B cells)
What this could lead to: If successful, this could lead to a new treatment option for rheumatoid arthritis that helps control the disease by targeting immune cells.
What could go wrong: This is a very early, small Phase 1 trial focused on safety, not effectiveness. The drug may cause side effects like cytokine release syndrome, and it may not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS (RA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHEUMATOID ARTHRITIS (RA)

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Kali Therapeutics Trial Site
RECRUITING

Bayswater, Victoria, Australia

Contact Email: •••••@•••••
Kali Therapeutics Trial Site
RECRUITING

Auckland, NZ, New Zealand

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.